<DOC>
	<DOC>NCT00610012</DOC>
	<brief_summary>The purpose of this registry is to record information of therapy reality of metastatic or locally advanced Renal Cell Carcinoma by office-based medical oncologists in Germany.</brief_summary>
	<brief_title>Tumor Registry of Advanced Renal Cell Carcinoma</brief_title>
	<detailed_description>The RCC Registry is a prospective, longitudinal, nation wide cohort study that collects data on the treatment reality of patients with mRCC. At inclusion, data in patient characteristics, comorbidities, tumor characteristics, and previous treatments are collected. During the course of observation data on all systemic treatments, radiotherapies, surgeries, and outcome are documented. Patients are followed until death or for a maximum of 3 years.</detailed_description>
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Carcinoma, Renal Cell</mesh_term>
	<criteria>Patients with metastatic or locally advanced Renal Cell Carcinoma requiring therapy Start of first palliative therapy within 1 year before enrollment of patient to registry; since enrollment of 1000 Patients: start of first palliative therapy within 4 weeks before enrollment</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Advanced Renal Cell Carcinoma</keyword>
	<keyword>MRCC</keyword>
	<keyword>Therapy-reality</keyword>
	<keyword>Observation</keyword>
	<keyword>Registry</keyword>
	<keyword>RCC</keyword>
	<keyword>ARCC</keyword>
	<keyword>Germany</keyword>
	<keyword>Metastatic Renal Cell Carcinoma</keyword>
	<keyword>Renal Cell Carcinoma</keyword>
	<keyword>Renal Cell Cancer</keyword>
	<keyword>Sorafenib</keyword>
	<keyword>Sunitinib</keyword>
	<keyword>Interferon</keyword>
	<keyword>Interleukin</keyword>
	<keyword>Temsirolimus</keyword>
	<keyword>Pazopanib</keyword>
	<keyword>Cytokines</keyword>
	<keyword>VEGF</keyword>
</DOC>